SCHEMBL23575596

SCHEMBL23575596

COc1cc(-c2cn(C)c(=O)c3c2cnn3C)cc(OC)c1CN(C)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 16/20 0.49
BRD7 Q9NPI1 12/20 0.49
TAF1 P21675 2/20 0.49
TGFBR1 P36897 2/20 0.49
ACVR1 Q04771 2/20 0.49
CREBBP Q92793 2/20 0.49
CECR2 Q9BXF3 2/20 0.49
BRPF1 P55201 1/20 0.49
BPTF Q12830 1/20 0.49
TAF1L Q8IZX4 1/20 0.49
BAZ2B Q9UIF8 1/20 0.49
ATAD2B Q9ULI0 1/20 0.49
BRD4 O60885 12/20 0.48
BRD2 P25440 6/20 0.48
CYP2D6 P10635 1/20 0.35
ACVR2B Q13705 1/20 0.35
BRD8 Q9H0E9 1/20 0.35
CD274 Q9NZQ7 1/20 0.34
ITGA4 P13612 1/20 0.33
ITGB7 P26010 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23575675 0.88 BRD9 (0.53) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575686 0.88 BRD9 (0.48) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575321 0.85 BRD9 (0.45) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL33530594 0.84 BRD9 (0.69) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23589965 0.83 BRD9 (0.48) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575438 0.82 BRD9 (0.52) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23589992 0.82 BRD9 (0.41) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575291 0.77 BRD9 (0.45) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575617 0.76 BRD9 (0.47) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23575293 0.76 BRD9 (0.44) BRD9BRD7TAF1TGFBR1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 THERAPEUTICS, INC. (US) 2021-07-01 US disclosed
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 THERAPEUTICS, INC. (US) 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 RBBP9, MTHFD1, BRWD1 BRD9 5/4885BRD7 32/4885TAF1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.